I've spent the last 2 weeks reading papers from the company in regards to their antibiotic platform and the work appears solid to me (given my limitations in this field). The publications are even in relatively decent journals.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.